BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Performance

BioLineRx stock opened at $3.39 on Tuesday. The company has a market cap of $6.78 million, a PE ratio of -0.39 and a beta of 1.41. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. BioLineRx has a 1 year low of $3.24 and a 1 year high of $57.60. The company’s 50-day moving average is $7.57 and its two-hundred day moving average is $17.86.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($2.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.20) by $0.40. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. Equities analysts anticipate that BioLineRx will post -5.8 earnings per share for the current year.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc increased its holdings in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,974 shares of the biotechnology company’s stock after buying an additional 29,193 shares during the quarter. Atria Investments Inc owned 0.17% of BioLineRx worth $72,000 as of its most recent SEC filing. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.